<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482625</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00898</org_study_id>
    <secondary_id>UCI 06-30</secondary_id>
    <secondary_id>N01CN35160</secondary_id>
    <secondary_id>CDR0000547235</secondary_id>
    <nct_id>NCT00482625</nct_id>
  </id_info>
  <brief_title>Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Phase IIA Trial Testing Erlotinib as an Intervention Against Intraductal Pancreatic Mucinous Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor
      smaller and reduce the amount of normal tissue that needs to be removed. This phase II trial
      is studying how well erlotinib hydrochloride works in treating patients with pancreatic
      cancer that can be removed by surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To test the hypothesis that the activated epidermal growth factor receptor (EGFR) signal
      transduction biomarker Mucin 5AC (MUC5AC) protein expression within intraductal pancreatic
      mucinous neoplasm (IPMN) lesions will have greater than zero absolute mean decrease from
      baseline comparing pre and post 21-42 days of Erlotinib (erlotinib hydrochloride)
      administration at 100mg orally (PO) once daily (QD).

      SECONDARY OBJECTIVES:

      I. To test the hypothesis that other correlative IPMN EGF inducible biomarkers will have
      greater than zero absolute mean decrease from baseline pre and post Erlotinib 100mg PO QD
      therapy.

      II. Safety of Erlotinib treatment. III. To determine Erlotinib pharmacokinetic concentration
      in plasma and pancreatic tissue at the 100mg/day dose up to 42 days of therapy.

      OUTLINE:

      Patients receive erlotinib hydrochloride PO QD for 21-42 days in the absence of disease
      progression or unacceptable toxicity. Patients then undergo to pancreatectomy.

      After completion of study treatment, patients are followed up at 4-20 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The protocol has been completed prematurely (e.g., due to poor accrual, insufficient drug
    supply, IND closure).
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Number of Positive IPMN Celss and Staining Intensity After Treatment</measure>
    <time_frame>Pre-treatment and post-treatment</time_frame>
    <description>Number of participants showed a reduction in number of positive IPMN cells and staining intensity after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Calculated Concentration - OSI-774 (ng/mL)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Plasma concentration levels of Erlotinib (OSI-774)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreas Calculated Concentration - OSI-774 (ng/g)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Pancreatic tissue concentration levels of Erlotinib (OSI-774)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Calculated Concentration - OSI-420 (ng/mL)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Plasma concentration levels of Erlotinib (OSI-420)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreas Calculated Concentration - OSI-420 (ng/g)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Pancreatic tissue concentration levels of Erlotinib (OSI-420)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reported at Least 1 Adverse Event With a Grade of 3 and Above</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>The worst grade of pre-listed toxicity will be summarized by participant and by visit for each treatment group. Descriptive statistics (frequencies and percents) will be used to summarize data and hypotheses about group differences will be tested where appropriate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Intraductal Papillary Mucinous Neoplasm of the Pancreas</condition>
  <condition>Recurrent Pancreatic Cancer</condition>
  <condition>Stage IA Pancreatic Cancer</condition>
  <condition>Stage IB Pancreatic Cancer</condition>
  <condition>Stage IIA Pancreatic Cancer</condition>
  <condition>Stage IIB Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Undergo pancreatectomy</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>surgery, conventional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed IPMN histological diagnosis, endoscopic ultrasound fine needle aspiration
             (EUS-FNA) core biopsy tissue specimen with plan for pancreatic surgical resection;
             histological diagnosis should be within 6 months of entry into protocol

          -  Patients must have adequate bone marrow function at study entry

          -  White blood cell (WBC) &gt; 3,000

          -  Platelets &gt; 100,000/mm^3

          -  Hemoglobin &gt; 10 g/dL

          -  Plasma creatinine of &lt; 1.6 mg/dL

          -  Total bilirubin &lt; 1.5

          -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 1.5 x
             upper limit of normal

          -  Patients with evidence of obstructive lung disease (forced expiratory volume in one
             second [FEV1] &lt; 80% predicted and FEV1/forced vital capacity [FVC] ratio &lt; 90% of
             predicted value) as the etiology of a low diffusing capacity will still be eligible as
             long as the chest radiograph or computed tomography (CT) does not demonstrate
             interstitial changes

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Women of child-bearing potential and men taking study drug must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation

          -  Ability to understand, as well as sign the written informed consent document

          -  If a woman of child-bearing potential, must have a negative pregnancy test prior to
             study entry; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her study physician immediately

        Exclusion Criteria:

          -  Intake of EGFR antagonist, Erbitux (cetuximab)

          -  Previous history of sensitivity to Tarceva (erlotinib hydrochloride), Iressa
             (gefitinib), or Erbitux, such as a rash that is uncontrollable by topical steroids
             and/or antibiotics

          -  Uncontrollable diarrhea of any cause

          -  Active keratoconjunctivitis, or corneal surgery in the past three weeks

          -  Participants taking a known cytochrome P450 3A4 (CYP 3A4) inducer (e.g., phenytoin,
             carbamazepine, St. John's wort, and rifampin) and medications known to be inhibitors
             or metabolized by CYP3A4; these inhibitors include erythromycin, clarithromycin and
             ketoconazole, and patients taking them will be excluded since these drugs may be
             expected to result in altered exposure of Erlotinib

          -  Hospitalization within the past 5 years for mania or for bipolar disease

          -  Participants may not be receiving any other investigational pharmaceutical agents

          -  Women who are breast-feeding should not receive Erlotinib

          -  Any medical or psychosocial condition that, in the opinion of the investigator, could
             jeopardize the subject's participation in and compliance to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Lipkin, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Medical Center At Irvine-Orange Campus</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL Jr. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope. 2003 Oct;113(10):1687-702. Review.</citation>
    <PMID>14520092</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <results_first_submitted>April 18, 2014</results_first_submitted>
  <results_first_submitted_qc>April 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2014</results_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
erlotinib hydrochloride: Given PO
conventional surgery: Undergo pancreatectomy
immunohistochemistry staining method: Correlative studies
protein expression analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
erlotinib hydrochloride: Given PO
conventional surgery: Undergo pancreatectomy
immunohistochemistry staining method: Correlative studies
protein expression analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.17" spread="14.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Number of Positive IPMN Celss and Staining Intensity After Treatment</title>
        <description>Number of participants showed a reduction in number of positive IPMN cells and staining intensity after treatment</description>
        <time_frame>Pre-treatment and post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
erlotinib hydrochloride: Given PO
conventional surgery: Undergo pancreatectomy
immunohistochemistry staining method: Correlative studies
protein expression analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Number of Positive IPMN Celss and Staining Intensity After Treatment</title>
          <description>Number of participants showed a reduction in number of positive IPMN cells and staining intensity after treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Calculated Concentration - OSI-774 (ng/mL)</title>
        <description>Plasma concentration levels of Erlotinib (OSI-774)</description>
        <time_frame>20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
erlotinib hydrochloride: Given PO
conventional surgery: Undergo pancreatectomy
immunohistochemistry staining method: Correlative studies
protein expression analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Calculated Concentration - OSI-774 (ng/mL)</title>
          <description>Plasma concentration levels of Erlotinib (OSI-774)</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428.5" spread="290.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pancreas Calculated Concentration - OSI-774 (ng/g)</title>
        <description>Pancreatic tissue concentration levels of Erlotinib (OSI-774)</description>
        <time_frame>20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
erlotinib hydrochloride: Given PO
conventional surgery: Undergo pancreatectomy
immunohistochemistry staining method: Correlative studies
protein expression analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pancreas Calculated Concentration - OSI-774 (ng/g)</title>
          <description>Pancreatic tissue concentration levels of Erlotinib (OSI-774)</description>
          <units>ng/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.7" spread="121.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Calculated Concentration - OSI-420 (ng/mL)</title>
        <description>Plasma concentration levels of Erlotinib (OSI-420)</description>
        <time_frame>20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
erlotinib hydrochloride: Given PO
conventional surgery: Undergo pancreatectomy
immunohistochemistry staining method: Correlative studies
protein expression analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Calculated Concentration - OSI-420 (ng/mL)</title>
          <description>Plasma concentration levels of Erlotinib (OSI-420)</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pancreas Calculated Concentration - OSI-420 (ng/g)</title>
        <description>Pancreatic tissue concentration levels of Erlotinib (OSI-420)</description>
        <time_frame>20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
erlotinib hydrochloride: Given PO
conventional surgery: Undergo pancreatectomy
immunohistochemistry staining method: Correlative studies
protein expression analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pancreas Calculated Concentration - OSI-420 (ng/g)</title>
          <description>Pancreatic tissue concentration levels of Erlotinib (OSI-420)</description>
          <units>ng/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reported at Least 1 Adverse Event With a Grade of 3 and Above</title>
        <description>The worst grade of pre-listed toxicity will be summarized by participant and by visit for each treatment group. Descriptive statistics (frequencies and percents) will be used to summarize data and hypotheses about group differences will be tested where appropriate.</description>
        <time_frame>Up to 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
erlotinib hydrochloride: Given PO
conventional surgery: Undergo pancreatectomy
immunohistochemistry staining method: Correlative studies
protein expression analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reported at Least 1 Adverse Event With a Grade of 3 and Above</title>
          <description>The worst grade of pre-listed toxicity will be summarized by participant and by visit for each treatment group. Descriptive statistics (frequencies and percents) will be used to summarize data and hypotheses about group differences will be tested where appropriate.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events are reported and docuemted during the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
erlotinib hydrochloride: Given PO
conventional surgery: Undergo pancreatectomy
immunohistochemistry staining method: Correlative studies
protein expression analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DRY EYES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>DIFFICULTY DIGESTING FOOD-UPPER GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>LOSS OF APPETITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>OUT OF RANGE LYMPHOCYTE VALUE-CLINICALLY SIGNIFICANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>OUT OF RANGE NEUTROPHIL VALUE-CLINICALLY SIGNIFICANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>OUT OF RANGE WBC VALUE-CLINICALLY SIGNIFICANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>LEG, FOOT, ANKLE CRAMPS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>DRY SKIN ON BODY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>DRY SKIN ON CHEEK AND CORNERS OF MOUTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Lipkin</name_or_title>
      <organization>Weill Cornell College of Medicine</organization>
      <phone>212-774-7160</phone>
      <email>stl2012@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

